You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股》撥康視雲(02592.HK)今起招股 入場費5,100.9元
阿思達克 06-24 08:25
臨床階段眼科生物科技公司撥康視雲-B(02592.HK)公布在港首次公開發售(IPO)詳情,計劃全球發售6,058.2萬股,當中國際配售部分佔90%(5,452.35萬股),香港公開發售佔10%(605.85萬股),發售價為每股10.1元,預料集資近6.12億元。每手買賣單位500股,入場費約5,100.94元。招股期由今日(24日)起至周五(27日)止,預計會於7月3日掛牌上市。聯席保薦人為建銀國際及華泰國際。 按發售價10.1元計,集資所得淨額約5.22億元,其中約62.4%將用於核心產品CBT-001的臨床研發活動,約27.6%用於撥付持續臨床研發活動及核心產品CBT-009的註冊備案,約5.5%用於生產設施及商業化活動,餘下4.5%為營運資金與一般企業用途。 是次招股引入2個基石投資者,包括中源協和細胞基因工程董事長龔虹嘉旗下的富策控股,以及投資機構The Reynold Lemkins Group (Asia) Limited,分別投資2,000萬美元及280萬美元,合共認購約1,772萬股發售股份,佔是次發售股份約29.25%。(gc/W)~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account